Corvus Pharmaceuticals IncNASDAQ:CRVS
- LAST PRICE9.0900
- TODAY'S CHANGE (%)-0.3300 (-3.5032%)
- Bid / Lots9.0100/ 3
- Ask / Lots9.4500/ 9
- Open / Previous Close9.5000 / 9.4200
- Day Range
- 52 Week Range
- Volume321,732
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRVS |
|---|---|---|
| 09:32 ET | 13676 | 9.44 |
| 09:33 ET | 350 | 9.43 |
| 09:35 ET | 400 | 9.43 |
| 09:37 ET | 700 | 9.49 |
| 09:39 ET | 200 | 9.435 |
| 09:42 ET | 455 | 9.4378 |
| 09:44 ET | 1850 | 9.35 |
| 09:46 ET | 6463 | 9.28 |
| 09:48 ET | 550 | 9.38 |
| 09:50 ET | 1200 | 9.32 |
| 09:51 ET | 550 | 9.345 |
| 09:53 ET | 1700 | 9.345 |
| 09:55 ET | 500 | 9.345 |
| 09:57 ET | 800 | 9.27 |
| 10:00 ET | 900 | 9.33 |
| 10:02 ET | 500 | 9.33 |
| 10:04 ET | 6024 | 9.35 |
| 10:06 ET | 1300 | 9.37 |
| 10:08 ET | 3195 | 9.5 |
| 10:09 ET | 200 | 9.46 |
| 10:11 ET | 400 | 9.46 |
| 10:13 ET | 8108 | 9.44 |
| 10:15 ET | 1000 | 9.495 |
| 10:18 ET | 300 | 9.495 |
| 10:20 ET | 2428 | 9.39 |
| 10:22 ET | 100 | 9.4 |
| 10:24 ET | 415 | 9.4 |
| 10:26 ET | 2983 | 9.46 |
| 10:27 ET | 1653 | 9.375 |
| 10:29 ET | 1450 | 9.36 |
| 10:31 ET | 1789 | 9.355 |
| 10:33 ET | 1600 | 9.365 |
| 10:36 ET | 3819 | 9.29 |
| 10:38 ET | 1300 | 9.32 |
| 10:40 ET | 500 | 9.315 |
| 10:42 ET | 2290 | 9.33 |
| 10:45 ET | 2202 | 9.345 |
| 10:47 ET | 204 | 9.33 |
| 10:49 ET | 450 | 9.33 |
| 10:51 ET | 1323 | 9.35 |
| 10:54 ET | 400 | 9.35 |
| 10:56 ET | 912 | 9.39 |
| 10:58 ET | 700 | 9.39 |
| 11:00 ET | 1029 | 9.36 |
| 11:02 ET | 1050 | 9.345 |
| 11:03 ET | 1500 | 9.3625 |
| 11:07 ET | 3047 | 9.37 |
| 11:09 ET | 1028 | 9.34 |
| 11:12 ET | 400 | 9.365 |
| 11:14 ET | 2121 | 9.43 |
| 11:16 ET | 300 | 9.41 |
| 11:18 ET | 2428 | 9.34 |
| 11:20 ET | 700 | 9.32 |
| 11:21 ET | 500 | 9.3 |
| 11:23 ET | 22570 | 9.35 |
| 11:25 ET | 8525 | 9.305 |
| 11:27 ET | 4400 | 9.33 |
| 11:30 ET | 1150 | 9.32 |
| 11:32 ET | 3083 | 9.32 |
| 11:34 ET | 100 | 9.32 |
| 11:36 ET | 2221 | 9.34 |
| 11:38 ET | 200 | 9.34 |
| 11:39 ET | 4322 | 9.32 |
| 11:41 ET | 744 | 9.31 |
| 11:43 ET | 2538 | 9.3228 |
| 11:45 ET | 300 | 9.335 |
| 11:48 ET | 1100 | 9.345 |
| 11:50 ET | 3610 | 9.35 |
| 11:52 ET | 5514 | 9.35 |
| 11:54 ET | 954 | 9.35 |
| 11:56 ET | 900 | 9.39 |
| 11:57 ET | 300 | 9.4 |
| 11:59 ET | 1335 | 9.399 |
| 12:01 ET | 500 | 9.39 |
| 12:03 ET | 1390 | 9.37 |
| 12:06 ET | 1412 | 9.35 |
| 12:08 ET | 780 | 9.34 |
| 12:10 ET | 600 | 9.35 |
| 12:12 ET | 300 | 9.32 |
| 12:14 ET | 877 | 9.31 |
| 12:15 ET | 950 | 9.29 |
| 12:17 ET | 300 | 9.29 |
| 12:19 ET | 1300 | 9.29 |
| 12:21 ET | 2150 | 9.3 |
| 12:24 ET | 7787 | 9.26 |
| 12:26 ET | 3500 | 9.25 |
| 12:28 ET | 9474 | 9.22 |
| 12:30 ET | 2727 | 9.25 |
| 12:32 ET | 1400 | 9.25 |
| 12:33 ET | 300 | 9.25 |
| 12:35 ET | 1000 | 9.275 |
| 12:37 ET | 4492 | 9.29 |
| 12:39 ET | 4001 | 9.23 |
| 12:42 ET | 2057 | 9.2161 |
| 12:44 ET | 3581 | 9.22 |
| 12:46 ET | 1100 | 9.26 |
| 12:48 ET | 902 | 9.24 |
| 12:50 ET | 6255 | 9.16 |
| 12:51 ET | 4300 | 9.16 |
| 12:53 ET | 3255 | 9.18 |
| 12:55 ET | 3309 | 9.13 |
| 12:57 ET | 2327 | 9.125 |
| 01:00 ET | 34789 | 9.09 |
Nov 14, 2024
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis, from 10:01AM ET on Thursday Nov 14, 2024 by Dow Jones
10:01AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 13, 2024
DJ Corvus Pharmaceuticals Is Maintained at Outperform by Oppenheimer, from 9:51AM ET on Wednesday Nov 13, 2024 by Dow Jones
9:51AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones*DJ Corvus Pharmaceuticals 3Q Loss/Shr 60c >CRVS, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 9, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Corvus Pharmaceuticals Inc | 605.3M | -9.8x | --- |
Tourmaline Bio Inc | 610.8M | -15.5x | --- |
Mind Medicine (MindMed) Inc | 594.7M | -4.1x | --- |
Savara Inc | 593.8M | -7.5x | --- |
Astria Therapeutics Inc | 592.6M | -5.0x | --- |
Third Harmonic Bio Inc | 590.7M | -13.2x | --- |
Company Information
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
Contact Information
- Headquarters
- 863 Mitten Rd Ste 102BURLINGAME, CA, United States 94010-1311
- Phone
- 650-900-4520
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Richard Miller
- Chief Financial Officer
- Leiv Lea
- Senior Vice President, Chief Business Officer
- Jeffrey Arcara
- Senior Vice President - Pharmaceutical Development
- William Jones
- Independent Director
- Ian Clark
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $605.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 64.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.06 |
EPS | $-0.93 |
Book Value | $0.79 |
P/E Ratio | -9.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
